The PREVER Study

  • Sandra Costa Fuchs
  • Flávio Danni Fuchs
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)


The PREVER study addressed two open issues in the management of prehypertension and hypertension. The PREVER-PREVENTION trial evaluated the effectiveness of a low dose of chlorthalidone with amiloride in the prevention of hypertension and target organ damage. The PREVER-TREATMENT trial compared the BP-lowering effect of diuretics and angiotensin receptor blockers and their BP effects on surrogate outcomes. Both were randomized, parallel, double-blind, controlled trials, conducted in parallel in 21 Brazilian academic centers, with 730 and 655 participants, respectively. Participants were eligible if remained with prehypertension or Stage-1 hypertension, respectively, after 3 months of lifestyle intervention. The incidence of hypertension was significantly lower along 18 months of follow-up in participants allocated to diuretics compared to placebo (hazard ratio 0.56, 95% CI 0.38–0.82). Left ventricular mass assessed by ECG indices decreased to a greater extent in participants allocated to diuretic.

In the PREVER-TREATMENT trial, participants randomized to chlorthalidone/amiloride had a more intense lowering of BP along the trial (2.3 mmHg on average of systolic BP, 95% CI: 1.2 to 3.3), despite the higher proportion of participants who had the initial dose doubled and used additional agents to control BP in the losartan arm. The findings of the PREVER-prevention trial underpins the recommendation for drug treatment of individuals with prehypertension who do not respond to recommendations to change their lifestyle. The findings of the PREVER-treatment trial show that the treatment of hypertension should start with effective BP-lowering agents such as diuretics.


Prehypertension Hypertension Blood pressure Left ventricular mass Blood pressure lowering agents Antihypertensive Randomized controlled trial Clinical trial Adverse event Prevention 



Sources of Funding: The Ministry of Health, Division of Science and Technology (DECIT), and Ministry of Science and Technology, Brazilian Innovation Agency (FINEP) (number 01080606/01), National Counsel of Technological and Scientific Development (CNPq), National Institute of Health Technology Assessment (IATS), and Hospital de Clinicas de Porto Alegre (FIPE-GPPG: 08621), RS, Brazil sponsored the PREVER study.


  1. 1.
    Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and SBP of at least 110 to 115 mm hg, 1990–2015. JAMA. 2017;317:165–82.CrossRefPubMedGoogle Scholar
  2. 2.
    World Health Report. Reducing risks, promoting healthy life. Geneva: World Health Organization; 2002. p. 2002.Google Scholar
  3. 3.
    Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441–50.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Picon RV, Fuchs FD, Moreira LB, Riegel G, Fuchs SC. Trends in prevalence of hypertension in Brazil: a systematic review with meta-analysis. PLoS One. 2012;7:e48255.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Picon RV, Fuchs FD, Moreira LB, Fuchs SC. Prevalence of hypertension among elderly persons in urban Brazil: a systematic review with meta-analysis. Am J Hypertens. 2013;26:541–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Moraes RS, Fuchs FD, Moreira LB, Wiehe M, Pereira GM, Fuchs SC. Risk factors for cardiovascular disease in a Brazilian population-based cohort study. Int J Cardiol. 2003;90:205–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.CrossRefGoogle Scholar
  8. 8.
    Fuchs FD. Essentials of hypertension. New York: Springer; 2017.Google Scholar
  9. 9.
    World Health Organization. Expert Committee on Cardiovascular Diseases and Hypertension & World Health Organization. Hypertension and coronary heart disease: classification and criteria for epidemiological studies, first report of the Expert Committee on Cardiovascular Diseases and Hypertension, Geneva, 13–18 October 1958. Geneva: World Health Organization; 1959. Scholar
  10. 10.
    Julius S. Classification of hypertension. In: Genest J, Koiw E, Kuchel O, editors. Hypertension. New York: McGraw-Hill; 1977. p. 9–12.Google Scholar
  11. 11.
    Julius S. Borderline hypertension. In: Genest J, Koiw E, Kuchel O, editors. Hypertension. New York: McGraw-Hill; 1977. p. 630–40.Google Scholar
  12. 12.
    Julius S, Ellis CN, Pascual AV, Matice M, Hansson L, Hunyor SN, et al. Home BP determination. Value in borderline (“labile”) hypertension. JAMA. 1974;229:663–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high BP: the JNC 7 report. JAMA. 2003;289:2560–71.CrossRefGoogle Scholar
  14. 14.
    Moreira LB, Fuchs SC, Wiehe M, Gus M, Moraes RS, Fuchs FD. Incidence of hypertension in Porto Alegre, Brazil: a population-based study. J Hum Hypertens. 2008;22:48–50.CrossRefGoogle Scholar
  15. 15.
    Markus MR, Stritzke J, Lieb W, Mayer B, Luchner A, Döring A, et al. Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: the MONICA/KORA Augsburg study. J Hypertens. 2008;26:2040–9.CrossRefGoogle Scholar
  16. 16.
    He J, Gu D, Chen J, Wu X, Kelly TN, Huan J. Premature deaths attributable to BP in China: a prospective cohort study. Lancet. 2009;374:1765–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Santos AB, Gupta DK, Bello NA, Gori M, Claggett B, Fuchs FD, Shah AM, Coresh J, Sharrett AR, Cheng S, Solomon SD. Prehypertension is associated with abnormalities of cardiac structure and function in the atherosclerosis risk in communities study. Am J Hypertens. 2016;29:568–74.CrossRefGoogle Scholar
  18. 18.
    Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA, Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685–97.CrossRefGoogle Scholar
  19. 19.
    Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P, PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal BP: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487–96.CrossRefGoogle Scholar
  20. 20.
    Fuchs SC, Poli-de-Figueiredo CE, Figueiredo Neto JA, Scala LC, Whelton PK, Mosele F, de Mello RB, Vilela-Martin JF, Moreira LB, Chaves H, Mota Gomes M, de Sousa MR, Silva RP, Castro I, Cesarino EJ, Jardim PC, Alves JG, Steffens AA, Brandão AA, Consolim-Colombo FM, de Alencastro PR, Neto AA, Nóbrega AC, Franco RS, Sobral Filho DC, Bordignon A, Nobre F, Schlatter R, Gus M, Fuchs FC, Berwanger O, Fuchs FD. Effectiveness of Chlorthalidone Plus Amiloride for the prevention of hypertension: the PREVER-prevention randomized clinical trial. J Am Heart Assoc. 2016;5:e004248.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fuchs FD, Fuchs SC, Moreira LB, Gus M, Nobrega AC, Poli-de-Figueiredo CE, Mion D, Bortoloto L, Consolim-Colombo F, Nobre F, Coelho EB, Vilela-Martin JF, Moreno H Jr, Cesarino EJ, Franco R, Brandão AA, de Sousa MR, Ribeiro AL, Jardim PC, Neto AA, Scala LC, Mota M, Chaves H, Alves JG, Filho DC, Pereira e Silva R, Neto JA, Irigoyen MC, Castro I, Steffens AA, Schlatter R, de Mello RB, Mosele F, Ghizzoni F, Berwanger O. Prevention of hypertension in patients with prehypertension: protocol for the PREVER-prevention trial. Trials. 2011;12:65.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31:1925–38.CrossRefGoogle Scholar
  23. 23.
    Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161–86.CrossRefPubMedGoogle Scholar
  24. 24.
    Okin PM, Roman MI, Devereux BB, Borer JS, KIigtieId P. Electrocardiographic diagnosis of left ventricular hypertrophy by the time-voltage integral of the QRS. J Am Coll Cardiol. 1994;23:133–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013;2013(31):1281–57.CrossRefGoogle Scholar
  26. 26.
    Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Guideline Development Group Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.CrossRefPubMedGoogle Scholar
  27. 27.
    Fuchs FD. The corporate bias and the molding of prescription practices: the case of hypertension. Braz J Med Biol Res. 2009;42:224–8.CrossRefPubMedGoogle Scholar
  28. 28.
    The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981–97.CrossRefGoogle Scholar
  29. 29.
    Thomopoulos C, Parati G, Zanchetti A. Effects of BP lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses. J Hypertens. 2015;33:195–211.CrossRefGoogle Scholar
  30. 30.
    Fuchs FD. The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment? Evid Based Med. 2013;18:44–7.CrossRefGoogle Scholar
  31. 31.
    Fuchs FD, DiNicolantonio JJ. Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand? Open Heart. 2015;2:e000236.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.CrossRefGoogle Scholar
  33. 33.
    Yusuf S, Sleight P, Anderson C, Teo K, Copland I, Ramos B, et al., TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008;372:1174–83.CrossRefGoogle Scholar
  34. 34.
    Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, et al., PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    McMurray JJ, Holman RR, Haffner SM, Bethel A, Holzhauer B, Hua TA, et al., NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477–90.CrossRefGoogle Scholar
  36. 36.
    Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, et al., ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364:928–38.CrossRefGoogle Scholar
  37. 37.
    Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17.CrossRefGoogle Scholar
  38. 38.
    Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda H, et al. ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978–86.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, et al., GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–17.CrossRefPubMedGoogle Scholar
  40. 40.
    Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial. Circ Arrhythm Electrophysiol. 2012;5:43–51.CrossRefPubMedGoogle Scholar
  41. 41.
    Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, et al. Randomized trial of angiotensin II-receptor blocker versus dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension ( J-RHYTHM II Study). Europace. 2011;13:473–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342:d2234.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, Boersma E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33:2088–97.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174:773–85.CrossRefGoogle Scholar
  45. 45.
    Elgendy IY, Huo T, Chik V, Pepine CJ, Bavry AA. Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials. Am J Hypertens. 2015;28:576–85.CrossRefGoogle Scholar
  46. 46.
    Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ. 2017;356:j4.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Retraction. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2009;374:1226.CrossRefGoogle Scholar
  48. 48.
    Retraction. Valsartan in a Japanese population with hypertension and other cardiovascular disease (JIKEI HEART STUDY): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2013;382:843.CrossRefGoogle Scholar
  49. 49.
    Retraction. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2013;34:1023.CrossRefGoogle Scholar
  50. 50.
    Thomopoulos C, Parati G, Zanchetti A. Effects of BP lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015;33:1321–41.CrossRefGoogle Scholar
  51. 51.
    Fuchs FD, Scala LC, Vilela-Martin JF, Bandeira-de-Mello R, Mosele F, Whelton PK, et al. Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-TREATMENT randomized trial. J Hypertens. 2016;34:798–806.CrossRefPubMedGoogle Scholar
  52. 52.
    Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59:1110–7.CrossRefGoogle Scholar
  53. 53.
    Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office BP. Hypertension. 2006;47:352–8.CrossRefGoogle Scholar
  54. 54.
    Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on BP, serum potassium, and urate. Hypertension. 2012;59:1104–9.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV, Kshirsagar PP, et al. Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory BP monitoring. J Am Coll Cardiol. 2016;67:379–89.CrossRefGoogle Scholar
  56. 56.
    Guerrero P, Fuchs FD, Moreira LM, Martins VM, Bertoluci C, Fuchs SC, et al. BP-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled BP receiving hydrochlorothiazide. Clin Exp Hypertens. 2008;30:553–64.CrossRefGoogle Scholar
  57. 57.
    Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48:1–6.CrossRefGoogle Scholar
  58. 58.
    Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and BP (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4:136–47.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Fuchs FD, Fuchs SC, Moreira LB, Gus M, Nóbrega AC, Poli-de-Figueiredo CE, et al. A comparison between diuretics and angiotensin receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double blind controlled trial. Trials. 2011;12:53.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Sandra Costa Fuchs
    • 1
  • Flávio Danni Fuchs
    • 2
  1. 1.Graduate Program in Cardiology, School of MedicineUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  2. 2.Division of Cardiology, Hospital de Clínicas de Porto Alegre, School of MedicineUniversidade Federal do Rio Grande do SulPorto AlegreBrazil

Personalised recommendations